Amadeus-backed Oxford Nanopore lists successfully on the LSE

Oxford Nanopore’s successful IPO is inspiring news for biotech entrepreneurs and a testament to the extraordinary vision of its founder and CEO Gordon Sanghera.

Oxford Nanopore image

Amadeus Capital Partners invested in the DNA-sequencing company last year, and what a year it’s been! Now one of the UK’s most valuable startups, Oxford Nanopore has showed the world the value of its technology as researchers used it to characterise the Covid-19 genome and track new variants.

If you want to find out how Oxford Nanopore’s electronics-based sequencers increase the accuracy and richness of genetic data and drive down costs, leading to better research and facilitating machine learning, read Amadeus partner Andrea Traversone’s insightful blog here.

Looking for something specific?